The Innovative Medicines Initiative funded ADAPTED project aimed to support the development of new medicines by investigating an area of Alzheimer’s disease research that has previously received little attention – the APOE gene.
The APOE gene is a well-known risk factor for developing the disease, but precisely how this gene contributes to the risk of developing Alzheimer’s disease isn’t clear yet. People who carry the APOE4 version of the gene have a higher risk of developing Alzheimer’s disease.
They also tend to develop the disease earlier in life.
However, the reasons for this are not well understood. By bringing together leading experts in a range of state-of-the-art technologies, ADAPTED hoped to gain better insights into the causes of Alzheimer’s disease, something that would in turn help to develop better treatments for patients.
Sample collections obtained from 1,193 individuals (blood, DNA, plasma, serum, saliva and CSF) have been generated by Fundació ACE and have been registered in the Spanish national registry of biobanks (Instituto de Salud Carlos III Reg. num. C.0000299).
The repository is accessible for research purposes to anyone interested. Sample access requests are reviewed and negotiated individually, regulated by Spanish legislation (Royal Decree 1716/2011; Act 14/2007) .
A Materials and Data transfer agreement (MDTA) is signed between Fundació ACE and research groups requesting access to this collection. For more information please visit:
The biosamples that were collected as part of the ADAPTED project are listed in Neuronet’s Asset Map, which provides a comprehensive view of the different assets resulting from the Innovative Medicines Initatives neurodegeneration research projects, including but not limited to genetic datasets, clinical cohorts and data platforms.
Explore it now: https://kb.imi-neuronet.org/admin/asset_map